173 related articles for article (PubMed ID: 31530783)
21. Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer.
Matsumoto A; Jinno H; Naruse S; Isono Y; Maeda Y; Sato A; Yamada M; Ikeda T; Sasajima Y
Jpn J Clin Oncol; 2023 Dec; 53(12):1119-1124. PubMed ID: 37609671
[TBL] [Abstract][Full Text] [Related]
22. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
Ogino M; Fujii T; Koibuchi Y; Nakazawa Y; Takata D; Shirabe K
Anticancer Res; 2021 Aug; 41(8):3899-3904. PubMed ID: 34281852
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial.
Shigematsu H; Kadoya T; Masumoto N; Sasada T; Emi A; Ohara M; Kajitani K; Okada M
Clin Breast Cancer; 2015 Apr; 15(2):110-6. PubMed ID: 25454688
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
Anticancer Res; 2018 Jan; 38(1):379-383. PubMed ID: 29277798
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer.
Xie F; Chen R; Zhang L; Yin Z; Zhu Q; You S; Jiang C; Li Y; Li S; Zha X; Wang J
Nanomedicine (Lond); 2019 Jun; 14(12):1595-1603. PubMed ID: 30977429
[No Abstract] [Full Text] [Related]
27. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
Matsui A; Tatibana A; Suzuki N; Hirata M; Oishi Y; Hamaguchi Y; Murata Y; Nagayama A; Iwata Y; Okamoto Y
Anticancer Res; 2017 Nov; 37(11):6481-6488. PubMed ID: 29061836
[TBL] [Abstract][Full Text] [Related]
30. Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial.
Kin T; Ohtani S; Maeda R; Ueno A; Fujihara M; Takamatsu Y; Kajiwara Y; Ito M; Kawasaki K; Abe K; Sakata Y; Hiraki K
World J Oncol; 2020 Oct; 11(5):197-203. PubMed ID: 33117463
[TBL] [Abstract][Full Text] [Related]
31. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
[TBL] [Abstract][Full Text] [Related]
32. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in Our Department].
Nakada T; Hosono Y
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1504-1506. PubMed ID: 30382059
[TBL] [Abstract][Full Text] [Related]
34. A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer.
Werner TL; Ray A; Lamb JG; VanBrocklin M; Hueftle K; Cohen AL; Beck AC; Buys SS; Dyess DL; Butler TW; Dumlao TL; Neumayer L; Khong HT
Clin Breast Cancer; 2017 Nov; 17(7):503-509. PubMed ID: 28579139
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
37. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and Safety of Neoadjuvant Chemotherapy Containing Nanoparticle Albumin-Bound Paclitaxel (NabPTX) in Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer].
Yoshioka S; Ota C; Moriguchi Y
Gan To Kagaku Ryoho; 2016 May; 43(5):579-82. PubMed ID: 27210086
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
